Monday, April 7, 2008

Light Sciences Oncology Names Holveck To Board

Cancer research firm Light Sciences Oncology Inc. revealed Monday that it has appointed David P. Holveck to its board of directors. Holveck, who becomes the boar'’s eighth member, is currently president, chief executive officer and a director of Endo Pharmaceuticals. Prior to Endo, Holveck served as vice president of corporate development and, later, president of Johnson & Johnson Development Corp. He also was president and CEO of Centocor Inc., which Johnson & Johnson acquired in 1999. Before Centecor, Holveck held positions with the General Electric, Corning Glass Works and Abbot Laboratories. Headquartered in Bellevue, Wash., Light Sciences Oncology is developing a novel, light-activated drug treatment for solid tumors.